newsfilter
← Latest News
PR Newswire·

RegeneRx Issues 2022 Letter To Stockholders

Update on Product Candidates, FDA Regulatory Strategy, Operations ROCKVILLE, Md., Aug. 22, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue pr